Anhui Huaheng Biotechnology Co. Ltd. A (688639) - Total Assets
Based on the latest financial reports, Anhui Huaheng Biotechnology Co. Ltd. A (688639) holds total assets worth CN¥6.03 Billion CNY (≈ $881.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 688639 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Anhui Huaheng Biotechnology Co. Ltd. A - Total Assets Trend (2012–2025)
This chart illustrates how Anhui Huaheng Biotechnology Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See 688639 total equity for net asset value and shareholders' equity analysis.
Anhui Huaheng Biotechnology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Anhui Huaheng Biotechnology Co. Ltd. A's total assets of CN¥6.03 Billion consist of 25.4% current assets and 74.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.9% |
| Accounts Receivable | CN¥587.63 Million | 10.2% |
| Inventory | CN¥532.13 Million | 9.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥150.04 Million | 2.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Anhui Huaheng Biotechnology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Anhui Huaheng Biotechnology Co. Ltd. A (688639) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anhui Huaheng Biotechnology Co. Ltd. A's current assets represent 25.4% of total assets in 2025, a decrease from 65.6% in 2012.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2025, down from 22.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
Anhui Huaheng Biotechnology Co. Ltd. A Competitors by Total Assets
Key competitors of Anhui Huaheng Biotechnology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Anhui Huaheng Biotechnology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 1.03 | 4.83 |
| Quick Ratio | 0.77 | 0.69 | 4.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥304.43 Million | CN¥40.62 Million | CN¥668.20 Million |
Anhui Huaheng Biotechnology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Anhui Huaheng Biotechnology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.55 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 15.7% |
| Total Assets | CN¥5.77 Billion |
| Market Capitalization | $624.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Anhui Huaheng Biotechnology Co. Ltd. A's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Anhui Huaheng Biotechnology Co. Ltd. A's assets grew by 15.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anhui Huaheng Biotechnology Co. Ltd. A (2012–2025)
The table below shows the annual total assets of Anhui Huaheng Biotechnology Co. Ltd. A from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.77 Billion ≈ $845.02 Million |
+15.74% |
| 2024-12-31 | CN¥4.99 Billion ≈ $730.11 Million |
+25.67% |
| 2023-12-31 | CN¥3.97 Billion ≈ $580.97 Million |
+95.86% |
| 2022-12-31 | CN¥2.03 Billion ≈ $296.63 Million |
+37.51% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.71 Million |
+98.43% |
| 2020-12-31 | CN¥742.89 Million ≈ $108.71 Million |
+32.40% |
| 2019-12-31 | CN¥561.09 Million ≈ $82.10 Million |
+3.69% |
| 2018-12-31 | CN¥541.13 Million ≈ $79.18 Million |
+31.32% |
| 2017-12-31 | CN¥412.06 Million ≈ $60.30 Million |
+6.74% |
| 2016-12-31 | CN¥386.04 Million ≈ $56.49 Million |
+33.49% |
| 2015-12-31 | CN¥289.20 Million ≈ $42.32 Million |
+52.28% |
| 2014-12-31 | CN¥189.91 Million ≈ $27.79 Million |
+2.66% |
| 2013-12-31 | CN¥184.98 Million ≈ $27.07 Million |
+46.92% |
| 2012-12-31 | CN¥125.90 Million ≈ $18.42 Million |
-- |
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material mon… Read more